
Movement Disorders Induced by Dopamine Blocking Agents

Daniel Dees MD Movement Disorders Program Director Associate Professor of Neurology University of South Alabama

Disclosures

- Accorda Pharma
- Amneal Pharma
- Kyowa Kirin Pharma
- Neurocrine Pharma
- Teva Pharma
- Supernus Pharma








Movement Disorders Induced by Dopamine Blocking Agents


- Chlorpromazine introduced in France in 1952 (Delay and Deniker)
- Soon afterwards, it was recognized that in addition to sedation these drugs were associated with other side effects
- Schonecker described abnormal neck movements (Tardive Dystonia)
- Uherbrand and Forbye described classic orobuccolingual dyskinesia





Relative Frequency of Dopamine blocking agents Induced Movement Disorders

- Classic TD from 1st gen D2 blockers
 30%
- Classic TD from 2nd gen D2 Blockers
 13%
- Drug induced parkinsonism
- 30%



Relative Frequency of Tardive Dyskinesia phenomenology

- 70% Tardive Chorea
- Tardive Dystonia
 30%
- Tardive Akathesia
 15%
- 1% Tardive tics

Relative Location of Tardive Dyskinesia phenomenology

- Oral/facial
- 70%
- Upper extremity
 65%
- Lower extremity 60%
- Trunk
- 50%





Pisa Syndrome






Tardive Dystonia Retrocollis



Tardive Akathesia



Severe Tardive Dyskinesia



Severe Tardive Dyskinesia



Which patients are at increased risk factors for TD?

- Cumulative exposure to
 Increased age antipsychotics
 Postmenopaus
- Treatment with anticholinergics
- Potency of DBA
- History of "EPS"
- Postmenopausal women
- Current substance abuse
- Diagnosis of mood disorder

Withdrawal -Emergent Syndrome

- The movements appear upon discontinuation of the DBA and last up-to 3 months
- More frequent in children
- The movements often choreic involve the limbs, neck, trunk primarily and seldom the lower facial region
- Another term is covert dyskinesia

Withdrawal emergent dyskinesia is real


- Communication with PCP and psychiatry
- Patient education
- Reasonable patient expectation



Tetrabenazine | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1-1 | 1

What is deuterium?


THE THREE ISOTOPES OF HYDROGEN



Can Stock Photo

One in every 6420 hydrogen atoms in the universe is a deuterium atom


Deuterated Tetrabenazine




Deuterium has greater mass Shifts electron density closer to

this side (tetrabenazine) (dutetrabenazine)

Deuterated Tetrabenazine





Drug Induced Parkinsonism

- 20-40% of patients treated with dopamine blocking agents
- Often subacute in onset and may resolve even with continuing use of the offending drugs
- More common and severe in older individuals
- May be tremor predominant or akinesia may overshadow other features
- Often asymmetrical

Parkinsonism



TD vs PD	-
TD-40917 TD DIP	
 The Washout time frame for drug induced parkinsonism is 6-12 months 	-
after stopping dopamine blockade.	
What about anticholinergics and "EPS"?	- <u></u>

Benztropine 2 mg

	_
What about Depakote?	
Drug Induced Tremor	
 DBA Induced Movement Disorders Prevention is the most important Patients on neuroleptics should be kept on the 	
lowest dosages possible and regularly evaluated for the continuing need for the DBA	
 Atypical agents should be used where possible 	
Questions?	
TARDIVE DYSKINESIA	
HAD ME-LIKE	